Diseases detected early using proteomic analysis – what then?
The quantum leap in the early and precise detection of diseases at the molecular level, where all diseases arise, presents medicine with new challenges. First of all, organ damage or loss of organ function can be prevented.
However, this requires targeted therapy. Every person responds differently to a medication for various reasons. High blood pressure/hypertension According to the comprehensive study by Stenström and colleagues, all drug groups would have to be tested by the treating doctors over a period of months and their effects checked. This fails not only because of the time and the constant documentation, but also because the respective stress or relaxation situations cannot be compared. No doctor has the time and no health system can afford these complex tests of patient reactions.
The technology from mosaiques enables the patient to be quickly and precisely adjusted to therapy, and not just for high blood pressure! Using the individual proteome, existing molecular dispositions and health events are analyzed and predicted with high - unparalleled - precision, and the individual reaction of the patient to the therapy received is mapped out based on their current reacting proteome.
Cardiovascular events, such as a Myocardial infarction and the resulting possible hospitalization, Heart failure or even the onset of death are predicted by the proteome at a time when the predicted course of events can be averted through individual therapy adjustment (lifestyle changes and medication). This has been shown by studies on thousands of patients.
The proteomic tests from mosaiques also enable the early detection of
Bile duct cancer
and thus the urgent need or exclusion of a liver transplant in cases of bile duct inflammation. Early proteomic therapy evaluation improves the current prognosis of invasive ERCP/imaging of 50% to over 95% and can also enable timely surgical removal of the carcinoma.
Also at
Prostate cancer
Proteomic analysis shows a significantly more accurate detection of aggressive carcinoma than the current clinical standard. Total removal of the prostate has been performed to date after a Gleason score of 3+4, which according to the Protect study is considered to be a non-aggressive carcinoma. In its scientific proteomic assessment, the proteomic comes to the same conclusion as the Protect study. The difference: proteomic analysis can carry out this diagnosis non-invasively and immediately at any time and provide a prognosis.
This knowledge of the proteome, stored in millions of data points in the proteome database including all clinical data, makes it possible to significantly reduce the risk of, for example, a cardiovascular event or an incorrect treatment decision. The database is only fed with data from qualified, published studies in cutting-edge medicine. The statements thus obtained enable individual therapy and dosage. Individual precision medicine is based on the artificial intelligence algorithms developed by the mosaiques tests, which have been and continue to be proven by scientific results in over 100 evidence-based studies.